OncoMatch/Clinical Trials/NCT05952024
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Is NCT05952024 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Rituximab and Acalabrutinib for diffuse large b-cell lymphoma.
Treatment: Acalabrutinib · Rituximab — The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
Adequate organ and marrow function independent of growth factor or transfusion support within 1 week of Screening.
Kidney function
Adequate organ and marrow function independent of growth factor or transfusion support within 1 week of Screening.
Liver function
Adequate organ and marrow function independent of growth factor or transfusion support within 1 week of Screening.
Adequate organ and marrow function independent of growth factor or transfusion support within 1 week of Screening.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · La Jolla, California
- Research Site · Orange, California
- Research Site · Jacksonville, Florida
- Research Site · Waukee, Iowa
- Research Site · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify